Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 283

1.

Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy.

Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2019 May 1. doi: 10.1002/cncr.32168. [Epub ahead of print]

PMID:
31042315
2.

Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer.

Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Apr 29. doi: 10.1038/s41391-019-0146-1. [Epub ahead of print]

PMID:
31036926
3.

Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.

Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.

Cancer. 2019 Apr 29. doi: 10.1002/cncr.32141. [Epub ahead of print]

PMID:
31034601
4.

Cancer diagnosis and risk of suicide after accounting for prediagnosis psychiatric care: A matched-cohort study of patients with incident solid-organ malignancies.

Klaassen Z, Wallis CJD, Chandrasekar T, Goldberg H, Sayyid RK, Williams SB, Moses KA, Terris MK, Nam RK, Urbach D, Austin PC, Kurdyak P, Kulkarni GS.

Cancer. 2019 Apr 25. doi: 10.1002/cncr.32146. [Epub ahead of print]

PMID:
31021430
5.

Editorial Comment.

Harper BT, Dykes TE, Terris MK.

J Urol. 2019 Apr;201(4):749. doi: 10.1097/01.JU.0000554775.94661.aa. No abstract available.

PMID:
30947464
6.

Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer.

Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Ravi SS, Robertson MJ, Piyarathna DWB, Villanueva M, von Rundstedt FC, Karanam B, Ballester LY, Terris MK, Bollag RJ, Lerner SP, Apolo AB, Villanueva H, Lee M, Sikora AG, Lotan Y, Sreekumar A, Coarfa C, Putluri N.

Clin Cancer Res. 2019 Mar 7. doi: 10.1158/1078-0432.CCR-18-1515. [Epub ahead of print]

PMID:
30846479
7.

The impact of psychiatric utilisation prior to cancer diagnosis on survival of solid organ malignancies.

Klaassen Z, Wallis CJD, Goldberg H, Chandrasekar T, Sayyid RK, Williams SB, Moses KA, Terris MK, Nam RK, Urbach D, Austin PC, Kurdyak P, Kulkarni GS.

Br J Cancer. 2019 Apr;120(8):840-847. doi: 10.1038/s41416-019-0390-0. Epub 2019 Mar 6.

PMID:
30837680
8.

Population-based outcomes of men with a single negative prostate biopsy: Importance of continued follow-up among older patients.

Sayyid RK, Alibhai SMH, Sutradhar R, Eberg M, Fung K, Klaassen Z, Goldberg H, Perlis N, Madi R, Terris MK, Urbach DR, Fleshner NE.

Urol Oncol. 2019 May;37(5):298.e19-298.e27. doi: 10.1016/j.urolonc.2019.01.030. Epub 2019 Feb 13.

PMID:
30770299
9.

First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ.

Cancer Causes Control. 2019 Mar;30(3):259-269. doi: 10.1007/s10552-019-1133-5. Epub 2019 Jan 30.

PMID:
30701374
10.

Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival.

Amara CS, Ambati CR, Vantaku V, Badrajee Piyarathna DW, Donepudi SR, Ravi SS, Arnold JM, Putluri V, Chatta G, Guru KA, Badr H, Terris MK, Bollag RJ, Sreekumar A, Apolo AB, Putluri N.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):770-781. doi: 10.1158/1055-9965.EPI-18-0936. Epub 2019 Jan 14.

PMID:
30642841
11.

Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.

Vantaku V, Donepudi SR, Piyarathna DWB, Amara CS, Ambati CR, Tang W, Putluri V, Chandrashekar DS, Varambally S, Terris MK, Davies K, Ambs S, Bollag R, Apolo AB, Sreekumar A, Putluri N.

Cancer. 2019 Mar 15;125(6):921-932. doi: 10.1002/cncr.31890. Epub 2019 Jan 2.

PMID:
30602056
12.

Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.

Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Urol Oncol. 2019 Apr;37(4):289.e11-289.e17. doi: 10.1016/j.urolonc.2018.12.004. Epub 2018 Dec 28.

PMID:
30598238
13.

EDITORIAL COMMENT.

Ericson CA, Terris MK.

Urology. 2018 Dec;122:49. doi: 10.1016/j.urology.2018.03.059. No abstract available.

PMID:
30552807
14.

EDITORIAL COMMENT.

Ericson CA, Terris MK.

Urology. 2018 Dec;122:43. doi: 10.1016/j.urology.2018.04.054. No abstract available.

PMID:
30552805
15.

Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.

Cancer. 2019 Feb 1;125(3):434-441. doi: 10.1002/cncr.31808. Epub 2018 Nov 14.

PMID:
30427535
16.

Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.

PMID:
30366879
17.

Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ; SEARCH Database Study Group.

BJU Int. 2018 Oct 22. doi: 10.1111/bju.14594. [Epub ahead of print]

PMID:
30347135
18.

Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ.

Prostate Cancer Prostatic Dis. 2019 May;22(2):252-260. doi: 10.1038/s41391-018-0095-0. Epub 2018 Oct 2.

PMID:
30279582
19.

Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ.

Int J Urol. 2018 Dec;25(12):998-1004. doi: 10.1111/iju.13806. Epub 2018 Sep 25.

PMID:
30253446
20.

Characterization and outcomes of local treatment for primary bladder lymphoma: A population-based cohort analysis.

Sellman DP, Simpson WG, Klaassen Z, Jen RP, DiBianco JM, Reinstatler L, Li Q, Madi R, Terris MK.

Urol Ann. 2018 Jul-Sep;10(3):249-253. doi: 10.4103/UA.UA_106_17.

Supplemental Content

Loading ...
Support Center